Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer
This recording from a series of expert-led small group meet-ups will increase your knowledge of RET inhibitors, help you gain confidence in utilizing biomarkers to inform treatment decisions, and improve collaboration between oncologists and pathologists to optimize precision medicine for RET-positive metastatic NSCLC and advanced thyroid cancer.
Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer
Clinical Commentary
Precision medicine continues to rapidly evolve in cancer care, and expert perspectives on recent advances can help you improve patient outcomes. This recording from a series of expert-led small group meet-ups will increase your knowledge of RET inhibitors, lead to greater confidence in utilizing biomarkers to inform your treatment decisions, and improve collaboration between oncologists and pathologists to optimize precision medicine for RET-positive metastatic NSCLC and advanced thyroid cancer.
Faculty: Marcia Brose, MD, PhD, FASCO and Justin Gainor, MD
Release Date:
Expiration Date: January 28, 2023
CME/CE is no longer available for this activity
